Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sweet & low: new treatment for diabetes that may reduce blood pressure.

× No keyword cloud information.

13 in total

1. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat.

Authors: S Vestri; M M Okamoto; H S de Freitas; R Aparecida Dos Santos; M T Nunes; M Morimatsu; J C Heimann; U F Machado
Journal: J Membr Biol Date: 2001-07-15 Impact factor: 1.843

2. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Authors: R L Dobbins; R O'Connor-Semmes; A Kapur; C Kapitza; G Golor; I Mikoshiba; W Tao; E K Hussey
Journal: Diabetes Obes Metab Date: 2011-10-30 Impact factor: 6.577

Review 3. Renal Na(+)-glucose cotransporters.

Authors: E M Wright
Journal: Am J Physiol Renal Physiol Date: 2001-01

4. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.

Authors: F R Macdonald; J E Peel; H B Jones; R M Mayers; L Westgate; J M Whaley; S M Poucher
Journal: Diabetes Obes Metab Date: 2010-11 Impact factor: 6.577

5. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Authors: Ele Ferrannini; Silvia Jimenez Ramos; Afshin Salsali; Weihua Tang; James F List
Journal: Diabetes Care Date: 2010-06-21 Impact factor: 19.112

6. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

Authors: Kenji Katsuno; Yoshikazu Fujimori; Yukiko Ishikawa-Takemura; Masayuki Isaji
Journal: Eur J Pharmacol Date: 2009-07-15 Impact factor: 4.432

Review 7. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.

Authors: L H Chen; P S Leung
Journal: Diabetes Obes Metab Date: 2013-02-06 Impact factor: 6.577

Review 8. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Authors: Kjeld Hermansen; Lene S Mortensen
Journal: Drug Saf Date: 2007 Impact factor: 5.606

9. Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

Authors: H S Freitas; G F Anhê; K F S Melo; M M Okamoto; M Oliveira-Souza; S Bordin; U F Machado
Journal: Endocrinology Date: 2007-10-25 Impact factor: 4.736

10. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Authors: B Komoroski; N Vachharajani; Y Feng; L Li; D Kornhauser; M Pfister
Journal: Clin Pharmacol Ther Date: 2009-01-07 Impact factor: 6.875